GIS:FRA
Gilead Sciences, Inc
130,88 €
arrow_upward
+0,28%(+0,36) 1D
9 okt, 22:00:00 GMT+2 · EUR
search
Bütün simvollar
| Simvol | Qiymət | Dəyişiklik | % Dəyişiklik |
|---|
insights_autoGIS üçün ən vacib statistik məlumatlar yaradılır...
Açın
130,88 €
Yüksək
130,88 €
Aşağı
130,88 €
Bazar kapitalizasiyası
187,44 mlrd
Ortalama həcm
398,00
Həcm
0,00
52 həftəlik ən yüksək
134,58 €
52 həftəlik ən aşağı
97,79 €
İşçilərin sayı
17K
Açın
130,88 €
Yüksək
130,88 €
Aşağı
130,88 €
Bazar kapitalizasiyası
187,44 mlrd
Ortalama həcm
398,00
Həcm
0,00
52 həftəlik ən yüksək
134,58 €
52 həftəlik ən aşağı
97,79 €
İşçilərin sayı
17K
Xəbər materialları
Veb mənbələri və xəbər partnyorlarından
AD HOC NEWS
·
1 saat öncə
Gilead Sciences stock gains 2.23 percent after-hours to EUR 134.13
AD HOC NEWS
·
7 saat öncə
RBC raises target for Gilead Sciences stock to USD 126.00
Simply Wall Street
·
15 saat öncə
How Earnings Beat At Gilead Sciences Stock Has Changed Its Investment Story
Yahoo Finance
·
1 gün öncə
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences, Inc haqqında
Baş İcraçı DirektorDaniel O'Day
İşçilər17K
Təsis Tarixi22 iyn 1987
Baş OfisFoster City, Kaliforniya, Amerika Birləşmiş Ştatları
Sektor-
Veb-saytgilead.com